A Clinical Study of Cizutamig in Thyroid Eye Disease

Inclusion Criteria: * 18-75 years old at the time of signing the Informed Consent Form * Diagnosis of Graves' Disease with active, moderate to severe TED in accordance with the Chinese Guidelines for the Diagnosis and Treatment of Thyroid-Associated Ophthalmology (2022) at Screening and Day 1 Exclusion Criteria: * Inadequate clinical laboratory parameters at Screening * Active infection present * Receipt of, or inability to discontinue, any of the excluded therapies * History of progressive multifocal leukoencephalopathy * History of primary immunodeficiency * Central nervous system disorders that the investigator considers would increase risk to the subject * Investigator-determined significant comorbidity(ies) * Have a diagnosis or history of malignant disease within 5 years prior to Screening * Active tuberculosis or lack of documentation of completed treatment for active pulmonary tuberculosis * History of severe allergic or anaphylactic reactions to mAb therapy (or recombinant antibody-related fusion proteins) or any constituents of cizutamig * Pregnant or breastfeeding women * Patients who do not agree to use highly effective contraception as specified in the protocol